What is Chemify?
Chemify is redefining the landscape of molecular discovery through its innovative Chemputation technology. By integrating advanced robotics with artificial intelligence, the company enables the translation of digital instructions into tangible chemical compounds. This approach effectively digitizes chemistry, allowing for the rapid synthesis of novel medicines and advanced materials at a global scale. Headquartered in Glasgow and founded by Lee Cronin, Chemify operates at the intersection of deep tech and life sciences, aiming to solve complex synthesis challenges that have historically hindered industrial progress. Its market position is characterized by a unique synthesis of software-defined hardware, providing a scalable infrastructure for researchers and industrial partners alike.
How much funding has Chemify raised?
Chemify has raised a total of $93M across 2 funding rounds:
Series A
$43M
Series B
$50M
Series A (2023): $43M with participation from Possible Ventures and Horizon Ventures
Series B (2025): $50M led by Triatomic Capital, Insight Partners, BlueYard Capital, 8VC, and Wing Venture Capital
Key Investors in Chemify
Triatomic Capital
Triatomic Capital is an investment firm focused on deep tech, health tech, and new economy sectors, particularly in AI and automation, supporting entrepreneurs developing century-defining technologies.
Insight Partners
Insight Partners is a global venture capital and private equity firm that invests in high-growth software and technology companies, providing capital and operational support to help businesses scale from early stage to IPO.
BlueYard Capital
BlueYard Capital is a venture capital firm that invests in innovative technologies across various sectors, including computation, engineering, biology, and cryptocurrency, backing transformative ideas that lead to a resilient society.
What's next for Chemify?
With the successful closure of this major strategic investment, Chemify is poised to expand its operational footprint and enhance its computational chemistry capabilities. The company's strategic roadmap focuses on scaling its Chemputation platform to support broader industrial applications, ranging from drug discovery to the development of high-performance materials. By utilizing this capital, Chemify intends to deepen its integration of AI-driven synthesis, further reducing the time-to-market for critical chemical innovations. As the firm matures, the focus will likely shift toward establishing strategic partnerships with global pharmaceutical entities and material science conglomerates, solidifying its role as a foundational technology provider in the digital chemistry ecosystem.
See full Chemify company page
